PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares surged 5.24% in the after-hours trading session on Tuesday, following the company's fourth quarter 2024 earnings report. The medical device company reported strong revenue growth and a narrower-than-expected loss for the quarter.
According to the earnings report, PROCEPT BioRobotics posted revenue of $68.24 million for the fourth quarter, a 56.6% increase compared to the same period last year. This figure beat analysts' consensus estimate of $66.78 million. The company's adjusted net loss per share of $0.35 also came in slightly better than the expected loss of $0.33 per share.
The solid financial performance and better-than-anticipated results suggest that PROCEPT BioRobotics' products and services are gaining traction in the market. Investors reacted positively to the news, driving the stock higher in the after-hours session as they anticipate continued growth and profitability for the company in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.